Findings based on review of national versus WHO guidelines

Time to sustained alleviation of COVID-19 symptoms not significantly shorter with nirmatrelvir-ritonavir versus placebo

Increase seen during pandemic period, following decrease between 1950 and 2019; child mortality continued to drop during pandemic.

Second booster dose resulted in 123,869 fewer hospitalizations and 5,524 fewer deaths versus single-dose campaign.